Sumitomo Dainippon Pharma to Collaborate with SOCIUM Joint Research Aims to Reveal Neuroprotective Mechanism in Tauopathy

SOCIUM Inc. (Head office: Chuo-ku, Tokyo, CEO: Dr. Hiroshi Kawai; “Socium”) announced that the company has entered into a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Mr. Hiroshi Nomura; “Sumitomo Dainippon Pharma”) for revealing the neuroprotective mechanism in tauopathy.

Click here for details (PDF).